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Abstract: Aims.
Data on predictors of time-to-first appropriate ICD therapy in patients with Brugada
syndrome (BrS) and prophylactically implanted ICD’s are scarce.
Methods.
SABRUS is an international survey on 678 BrS-patients who experienced arrhythmic
event (AE) including 252 patients in whom AE occurred after prophylactic ICD
implantation. Analysis was performed on time-to-first appropriate ICD discharge
regarding patients’ characteristics. Multivariate logistic regression models were utilized
to identify which parameters predicted time to arrhythmia ≤ 5 years.
Results.
The median time-to-first appropriate ICD therapy was 24.8±2.8 months. A shorter time
was observed in patients from Asian ethnicity (p<0.05), those with syncope (p=0.001)
and those with class IIa indication for ICD (p=0.001). A longer time was associated with
a positive family history of sudden cardiac death (p<0.05). Multivariate Cox regression
revealed shorter time-to-ICD therapy in patients with syncope (OR 1.65, P=0.001). In
193 patients (76.6%), therapy was delivered during the first 5 years. Factors
associated with this time were syncope (OR 0.36, p=0.001), spontaneous type 1
Brugada ECG (OR 0.5, p<0.05) and class IIa indication (OR 0.38, p<0.01) as opposed
to class IIb (OR 2.41, p<0.01). A near-significant trend for female gender was also
noted (OR 0.13, p=0.052). Two score models for prediction of <5 years to shock were
built.
Conclusions.
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First appropriate therapy in BrS-patients with prophylactic ICD’s occurred during the
first 5 years in 76.6% of patients. Syncope and spontaneous type 1 Brugada-ECG
correlated with a shorter time to ICD therapy.
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'What's New?'  
1. In patients with BrS who had an appropriate shock from a prophylactically implanted 
ICD, the great majority (76.6%) received this shock during the first 5 years after ICD 
implantation.  
2. Clinical parameters predicting a shorter time to appropriate shock were syncope and 
a spontaneous type 1 ECG. A near-significant trend for female gender was also 
noted. 
3. Two score models were built using these parameters to predict the time to first AE 
and will need to be validated in future studies.  
 
 
"What's New"
ABSTRACT 
Aims. 
Data on predictors of time-to-first appropriate ICD therapy in patients with Brugada 
syndrome (BrS) and prophylactically implanted ICD’s are scarce.  
Methods. 
SABRUS is an international survey on 678 BrS-patients who experienced arrhythmic event 
(AE) including 252 patients in whom AE occurred after prophylactic ICD implantation. 
Analysis was performed on time-to-first appropriate ICD discharge regarding patients’ 
characteristics. Multivariate logistic regression models were utilized to identify which 
parameters predicted time to arrhythmia ≤ 5 years.  
Results. 
The median time-to-first appropriate ICD therapy was 24.8±2.8 months. A shorter time was 
observed in patients from Asian ethnicity (p<0.05), those with syncope (p=0.001) and those 
with class IIa indication for ICD (p=0.001). A longer time was associated with a positive 
family history of sudden cardiac death (p<0.05). Multivariate Cox regression revealed 
shorter time-to-ICD therapy in patients with syncope (OR 1.65, P=0.001). In 193 patients 
(76.6%), therapy was delivered during the first 5 years. Factors associated with this time 
were syncope (OR 0.36, p=0.001), spontaneous type 1 Brugada ECG (OR 0.5, p<0.05) and 
class IIa indication (OR 0.38, p<0.01) as opposed to class IIb (OR 2.41, p<0.01). A near-
significant trend for female gender was also noted (OR 0.13, p=0.052). Two score models for 
prediction of <5 years to shock were built. 
Conclusions.  
First appropriate therapy in BrS-patients with prophylactic ICD’s occurred during the first 5 
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years in 76.6% of patients. Syncope and spontaneous type 1 Brugada-ECG correlated with a 
shorter time to ICD therapy. 
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First appropriate ICD therapy occurred during first 5 years in 76.6% of patients. Syncope and 
spontaneous type 1 Brugada-ECG (comprising class IIa indication for prophylactic ICD 
implantation) correlated with shorter time to ICD therapy. 
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Letter
ABSTRACT 
Aims. 
Data on predictors of time-to-first appropriate ICD therapy in patients with Brugada 
syndrome (BrS) and prophylactically implanted ICD’s are scarce.  
Methods. 
SABRUS is an international survey on 678 BrS-patients who experienced arrhythmic event 
(AE) including 252 patients in whom AE occurred after prophylactic ICD implantation. 
Analysis was performed on time-to-first appropriate ICD discharge regarding patients’ 
characteristics. Multivariate logistic regression models were utilized to identify which 
parameters predicted time to arrhythmia ≤ 5 years.  
Results. 
The median time-to-first appropriate ICD therapy was 24.8±2.8 months. A shorter time was 
observed in patients from Asian ethnicity (p<0.05), those with syncope (p=0.001) and those 
with class IIa indication for ICD (p=0.001). A longer time was associated with a positive 
family history of sudden cardiac death (p<0.05). Multivariate Cox regression revealed 
shorter time-to-ICD therapy in patients with syncope (OR 1.65, P=0.001). In 193 patients 
(76.6%), therapy was delivered during the first 5 years. Factors associated with this time 
were syncope (OR 0.36, p=0.001), spontaneous type 1 Brugada ECG (OR 0.5, p<0.05) and 
class IIa indication (OR 0.38, p<0.01) as opposed to class IIb (OR 2.41, p<0.01). A near-
significant trend for female gender was also noted (OR 0.13, p=0.052). Two score models for 
prediction of <5 years to shock were built. 
Conclusions.  
First appropriate therapy in BrS-patients with prophylactic ICD’s occurred during the first 5 
years in 76.6% of patients. Syncope and spontaneous type 1 Brugada-ECG correlated with a 
shorter time to ICD therapy. 
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Condensed abstract. 
SABRUS collected 252 patients in whom AE occurred after prophylactic ICD implantation. 
First appropriate ICD therapy occurred during first 5 years in 76.6% of patients. Syncope and 
spontaneous type 1 Brugada-ECG (comprising class IIa indication for prophylactic ICD 
implantation) correlated with shorter time to ICD therapy. 
  
'What's New?'  
1. In patients with BrS who had an appropriate shock from a prophylactically implanted 
ICD, the great majority (76.6%) received this shock during the first 5 years after ICD 
implantation.  
2. Clinical parameters predicting a shorter time to appropriate shock were syncope and 
a spontaneous type 1 ECG. A near-significant trend for female gender was also 
noted. 
3. Two score models were built using these parameters to predict the time to first AE 
and will need to be validated in future studies.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION 
Brugada syndrome (Brs) is a well-recognized cause of sudden cardiac death (SCD) 
particularly in apparently healthy middle-aged males(1). The cause of death is a ventricular 
tachyarrhythmia usually occurring without precipitating warning signs(2) .  Most clinical 
research on this potentially lethal arrhythmic disease has mainly focused on risk 
stratification to identify patients at risk who will benefit from an implanted cardioverter-
defibrillator (ICD), the most advocated option to prevent SCD.  
Present indications for prophylactic ICD implantation in patients with BrS-ECG include(3): 1) 
Spontaneous type 1 Brugada-ECG pattern and a history of syncope (class IIa indication); 2) 
Spontaneous or drug-induced type 1 Brugada-ECG with induction of ventricular fibrillation 
during programmed ventricular stimulation with 2 or 3 extrastimuli (class IIb indication). 
When a patient is identified as complying with these guideline recommendations(3), the 
most appropriate timing of the implantation is unknown with a double-edged sword 
decision for implant:  too early might expose the patient to possible complications whereas 
too late might have a detrimental outcome.  
SABRUS is a multicenter international survey that collected data on a large cohort (n= 678) 
of BrS-patients who experienced AE including 252 patients in whom the AE occurred after a 
prophylactic ICD implantation. 
The present study sought to gain insight into the factors that affect the time-to-first 
appropriate ICD therapy in all the 252 BrS patients who received a prophylactic ICD.  
 
 
METHODS   
Study group. As mentioned in previous papers(1, 2), the SABRUS cohort population 
comprised a total of 678 BrS-patients with AE who were recruited from 23 centers from 
both 10 Western countries (426 patients; 62.8%) and 4 Asian countries (252 patients; 
37.2%).  In 426 patients (group A), the AE was documented during aborted CA while in 252 
patients (group B) the AE was documented from an ICD implanted prophylactically following 
conventional class IIa or IIb indications(3) (75% of patients) or non-class IIa or IIb indications 
(25% of patients)(2). 
Group B patients comprised the study group of the present study.  
The study was approved by the Research Ethics Boards of all participating institutions. 
DATA ACQUISITION. 
Anonymous patient information was collected using a predefined questionnaire regarding 
the following: 1) gender; 2) patient age at time of ICD implantation; 3) date of ICD 
implantation; 4) date at which the first AE occurred after ICD implantation; 4) ethnicity 
(Caucasian, Asian, other or unknown); 5) proband status; 6) family history of SCD;  7) prior 
history of syncope ; 8) presence of spontaneous or drug-induced Brugada-ECG type 1; 7) 
inducibility of sustained ventricular fibrillation (VF) at EP study (EPS) and 9) results of genetic 
testing for the presence of SNC5A mutation. 
DEFINITIONS. 
Arrhythmic events: AE was defined as any sustained ventricular tachyarrhythmia triggering 
appropriate ICD shock therapy. 
STATISTICAL ANALYSIS.   
Estimation of median time to AE for ordinal variables was done using Kaplan-Meier curves; 
significance of the difference between two curves was calculated using the log-rank test. 
Multivariate time to AE analysis and analysis of continuous parameters was done using Cox 
regression models. Calculation of each parameter effect on probability of time to AE being 
>5 years was done using binary logistic regression models. To prevent detection bias due to 
patients with longer follow up having a longer time to AE, we added the year of ICD 
implantation in all of the multivariate analyses to cancel out this effect. Out of the 
multivariate logistic regression model we built prediction scores using the relative odd ratios 
as a guide to each parameter score. The trend between the scores and the above probability 
was assessed using Mantel-Haenszel test of trend and the highest-ranking scores were 
selected. Time to AE is shown as Median ± SE. P-values were considered significant when 
P<0.05, all calculations were done using SPSS v.24 from IBM, Armonk, Virginia.                    
RESULTS 
Study group.  The study group comprised 252 patients aged 1.1-77.5 (mean 46.1 ± 13.3) 
years at time of AE, most being males (n= 229, 91%) and Caucasians (n= 160, 63.5 %) 
(Supplemental Table 1).  A positive family history of SCD and a prior history of syncope were 
present in 29% and 63% of patients, respectively. A spontaneous type 1 Brugada-ECG was 
observed in 69% of patients. Most of the patients (79%) underwent an EPS during which VF 
was inducible in 72% of them. Genetic testing was performed in 67% of patients and 
revealed an SCN5A mutation in 36% of them. The age at time of ICD implantation ranged 
from 1-73.2 years (mean 43.4±13.1). 
Time-to-shock. The time-to-shock ranged from 0 to 168.4 months (median 24.4±2.8 
months), Figure 1 shows the Kaplan Meier curves for the entire time span. Table 1 
elaborates the comparison of the median time-to-shock according to different patient 
characteristics and Figure 2 displays the results. The following two factors were found to be 
associated with a significantly shorter time-to-shock: Asian vs. Caucasian ethnicity (16.5±4.8 
vs. 30.9±16.5 months respectively, P<0.05) and a prior history of syncope vs. being 
asymptomatic (19.5±2.5 vs. 36.5±4.9 months respectively, P=0.001). In contrast a positive 
family history of SCD resulted in a longer time-to-shock (33.5±4.8 vs. 21.2±3.1 months in 
patients without such a history, P<0.05). 
In respect to the conventional indications of prophylactic ICD implantation (3), the shortest 
median time-to-shock was observed in the class IIa subgroup (17.8±3.5 months) as 
compared to class IIb subgroup (37.2±4.2 months, P=0.001) or to non IIa/IIb indications 
(29.6±2.8 months, P=0.058)  
Univariate Cox regression for continuous variables did not find a significant relation 
between a shorter time-to-shock and patient age at time of ICD implantation [P=0.285; odds 
ratio [OR]. 1.06; 95% confidence interval (CI). 0.96-1.17]. Multivariate Cox regression was 
significant for a history of syncope [P=0.001; OR 1.65; 95% CI 1.21-2.25] and for year of ICD 
implantation [P<0.001; OR 1.12; 95% CI 1.07-1.16] but not for ethnicity or family history of 
SCD.  
Less than 5 years-to-shock time. Table 2 shows patients characteristics in respect to a 5 
years-to-shock time. In 193 (76.6%) patients appropriate ICD shock therapy was delivered 
during the first 5 years.  Univariate logistic regression (Figure 3) analyses showed that 
factors favoring this time lag were a prior history of syncope (P=0.001, OR. 0.36; 95% CI 0.2-
0.65), the presence of a spontaneous type 1 Brugada-ECG (P<0.05, OR. 0.5; 95% CI 0.27-
0.92) and the year of ICD implantation (P<0.001; OR. 0.87; 95% CI 0.82-0.94). Female gender 
showed a trend towards shock time less than 5 years (P=0.052, OR. 0.13; 95% CI 0.02-1.02), 
Multivariate Cox regression analysis was significant for all the aforementioned parameters 
(Supplemental Table 3).  
Opposite results were found between the class IIa and IIb indications for prophylactic ICD 
implantation: a class IIa indication was a significant predictor for < 5 years-to-appropriate 
shock (P<0.01; OR. 0.38; 95% CI 0.2-0.71) whereas a class IIb indication was a significant 
predictor for > 5 years-to-appropriate shock (P<0.01; OR. 2.41; 95% CI 1.32-4.22) (Figure 3). 
 Time-to-Shock Score. Taking into consideration the aforementioned patients’ 
characteristics predicting a time-to-shock < 5 years, their relative odds ratio, and parameter 
significance, two risks scores were built.  One with a history of syncope and spontaneous 
type 1 Brugada ECG (minimal score) and the second with female gender added, as it had a 
borderline significance, yet we postulated it could add power to the score (gender 
augmented score).   
These Scores sum the risk factors found to have significance for an earlier AE after a 
prophylactic ICD implantation. Each risk factor received a score between 1 and 2 and the 
sum gives the percentage of patients who received an appropriate therapy during the first 5 
years from the implant (Figure 4). One point is given for either prior syncope or the 
presence of a spontaneous type 1 Brugada-ECG, and for the gender augmented score - 2 
points were added for female gender. The scores range between 0 and 2 for the minimal 
score and 0 and 4 for the gender augmented score. A score of 0 was found in 50.0% of 
patients using the minimal score and in 46.4% of patients using the gender augmented 
score. A maximal score (2 in the minimal score system and 4 in the gender augmented 
system) was observed in 85% and 100% of patients, respectively. The trend between the 
score and the percentage of patients with time to shock less than 5 years was highly 
significant for both scores (p<0.001 for both) but reached a higher level for the gender 
augmented score (Mantel-Haenszel statistics of 16 and 20.1 for the minimal and the gender 
augmented scores, accordingly).  
DISCUSSION 
Our study showed that the median time-to-first appropriate ICD therapy in the 252 BrS 
patients who received a prophylactic ICD was 24.8±2.8 months. The shortest times were 
observed in patients of Asian ethnicity, in those with prior syncope and in those who had a 
class IIa indication for ICD implantation. The longest time was associated with a positive 
family history of SCD. In > 3 quarters of the study patients, appropriate ICD therapy was 
delivered during the first 5 years after implantation, especially in patients with a female 
gender, those with a prior syncope and those with a spontaneous type 1 Brugada-ECG. Two 
score models for predicting a time-to-shock ≤5 years were built according to the significance 
of the parameters; one included syncope and a type 1 Brugada ECG and the second included 
female gender which had a borderline significance and resulted in a 100% accuracy when 
patients exhibited all these characteristics. 
Time-to-shock. 
The literature regarding the time-to-first appropriate shock therapy in BrS patients 
implanted prophylactically with an ICD is scarce. Only 3 studies report their results on small 
patient cohorts (ranging from 7 to 34 patients)(4-6). Sarkozy et al.(5) found a mean time-to-
first appropriate therapy of 13 months (3 days to 4 years) in 7 male patients including 3 with 
a history of syncope. They did not find a significant predictor of appropriate shock-free 
survival(5). In an earlier study, Sacher et al.(4) demonstrated that the asymptomatic group 
(n=5) had a shorter median time-to-shock (16 months) than the syncope group (n=9) (24 
months)(4). However, in a latter larger study by the same group with prolonged follow-up 
duration, time-to-shock lengthened with no difference found between the symptomatic (47 
months, n=22) and asymptomatic (45 months, n=12) groups(6). 
 In the present study which involved the largest cohort population with AEs documented 
after prophylactic ICD implantation (n=252), the median time-to-shock was 24.8 months.  
Asian ethnicity and a history of syncope were predictors of a shorter time-to-shock, 
suggesting these factors should be taken into consideration when contemplating ICD 
implantation. This is consistent with the fact that group IIa patients had the shortest time-
to-shock.  
By multivariate logistic regression the presence of syncope was found to correlate with a 
shorter time-to-shock (19.5±2.5 months vs. 36.5±4.9 months in asymptomatic patients, 
P<0.001). It is noteworthy that these results are in agreement with those of the FINGER 
study(7) where time-to-first event was reported to be significantly shorter in the syncope 
group patients than in the asymptomatic group.  
In the present study, a positive family history of SCD correlated with a longer time-to-shock, 
however these findings should be considered with caution since they were seen only in the 
univariate analysis and not in the multivariate one. One possible explanation could be a 
biased decision taken by the referring patient’s physician who considered a family history of 
SCD as a major risk factor. On the other hand, we already stressed elsewhere the 
problematic definition of family history of SCD in our study(2).  ICD implant year was a 
predictor of early AE, mostly due to longer follow-up in patients that had an ICD implanted 
in the past, although this finding might also represent different trends in ICD implant 
indications, and changes in ICD arrhythmia detection algorithms.   
Time-to-shock within 5 years. 
Considering the lifesaving properties of ICD in comparison to its non-negligible complication 
rate together with the low incidence of AE requiring ICD intervention in BrS patients 
implanted prophylactically, up to a 5-year time-to-shock was chosen as accounting for a 
well-timed implant. Our study found that syncope and a spontaneous type 1 Brs-ECG were 
significantly associated with time-to-shock of ≤5 years. Therefore, it is not surprising that 
group IIa patients which included those with syncope and a spontaneous type 1 BrS-ECG 
belonged to this 5 years’ time-to-shock period. Moreover, the fact that in contrast group IIb 
patients exhibited their AE more than 5 years after implantation is in congruence with the 
lower risk of AE found in group IIb as compared to group IIa patients(8).  
Our study showed that 96% of female patients vs. 75% of males had their AE’s ≤ 5 years 
after ICD implant. In our recent paper(9) we discussed several factors suggesting a more 
aggressive course of the disease in females. This should support an early implantation of ICD 
in females found to be at high risk. 
Time-to-shock Score  
The time-to-shock score (TScore) was created to help the identification of patients who will 
need an ICD implant with the shortest delays. The significant risk factors found in our study 
to be associated with a time-to-shock ≤ 5 years were attributed a score according to their 
statistical significance. Because female gender had a borderline significance (p=0.052), 
which could be a result of the low number of females included in the study, we created two 
scores one including gender and one excluding it.  Both scores showed high prediction rates 
for AE ≤ 5 years after ICD implant, yet the gender augmented score showed a more 
significant trend with a higher predictive value for the maximal score (85% for the maximal 
score in the minimal scoring system vs. 100% for the gender augmented system). As 
indicated in Figure 3, the absence of any of these risk factors, results in a risk of ~50% 
chance of exhibiting an AE ≤ 5 years after ICD implant. Thus, patients with a score of 0 could 
be implanted less urgently. On the other hand, a maximal score of 4 (i.e. a female with 
syncope and a spontaneous type 1 BrS-ECG) in the gender augmented system should lead to 
ICD implant with the shortest delays. The value of this TScore should be further validated 
and assessed prospectively in future studies, where the question of the influence of gender 
could also be assessed more accurately. 
Limitations  
The present study by nature is a retrospective cumulative analysis of results from the largest 
EP-centers with experience with BrS. The decision to implant a prophylactic ICD in those 
patients who did not fulfill class II indications was left to the discretion of the treating 
physician. We acknowledge that defining risk factors without a comparative group of 
asymptomatic patients is problematic and that the results should be prospectively tested in 
future studies. Also, our cohort was probably not powered enough to assess the influence of 
female gender as resulted in a borderline significance for a time to shock of less than 5 
years.   
Conclusion 
The present study describes for the first time, in a large cohort of BrS patients with AE’s 
documented after prophylactic ICD implantation, the characteristics of those who exhibited 
their AE within 5 years.  Two factors (syncope and spontaneous type 1 BrS-ECG) were found 
to be associated with this time-to-shock delay.  A score based on these factors is proposed 
and should be assessed prospectively.  
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Table 1. Comparison of the median time-to-shock by different patient characteristics. 
 
 
    
Time-to-shock  
p-
value months 
(Median±SE) 
Overall   24.4±2.8   
Gender 
Male 25.3±3.2 
0.458 
Female 21.5±3.5 
Ethnicity 
Caucasian 30.9±16.5 
0.036 
Asian 16.5±4.8 
Family history of SCD 
Yes 33.5±4.8 
0.019 
No 21.2±3.1 
Prior history of syncope 
Yes 19.5±2.5 
0.001 
No 36.5±4.9 
Spontaneous type 1 ECG 
Yes 23.5±2 
0.258 
No  36.1±7.7 
VF inducibility during EPS 
Positive EPS 25.5±4.8 
0.426 
Negative EPS 24.2±6.9 
EPS not 
performed 
21.2±4.6 
Presence of SCN5A 
mutation 
SCN5A positive 22.6±5.2 
0.799 
SCN5A negative 24.4±4.2 
Class of indication for ICD 
IIa 17.8±3.5 
0.003*,# IIb 37.2±4.2 
No IIa or IIb 29.6±2.8 
 
 
 IIa vs. IIb, P=0.001; # IIa vs. No, P=0.058 
 
Table 2. Characteristics of patients in respect to the appropriate time-to-shock (less or 
more than 5 years) delivery.   
 
  
Time to AE 
p-value ≤5 years  >5 years 
193(76.6) 59(23.4) 
Gender 
Male 171(88.6) 58(98.3) 
0.045 
Female 22(11.4) 1(1.7) 
Ethnicity 
Caucasian 119(61.7) 41(69.5) 
0.48 
Asian 62(32.1) 16(27.1) 
Other 4(2.1) 0(0) 
0.613 
Unknown 8(4.1) 2(3.4) 
Family history of SCD 
Yes 52(26.9) 20(33.9) 
0.278 
No 122(63.2) 31(52.5) 
Unknown 19(9.8) 8(13.6) 0.571 
Prior history of syncope 
Yes 133(68.9) 26(44.1) 
0.001 
No 60(31.1) 33(55.9) 
Spontaneous type 1 ECG 
Yes 141(73.1) 34(57.6) 
0.037 
No  52(26.9) 25(42.4) 
VF inducibility during EPS 
Not performed  42(21.8) 10(16.9) 0.538 
Positive EPS 107(70.9) 37(75.5) 
0.529 
Negative EPS 44(29.1) 12(24.5) 
Presence of SCN5A mutation 
Not performed 60(31.1) 24(40.7) 0.226 
SCN5A positive 47(35.3) 14(40) 
0.609 
SCN5A negative 86(64.7) 21(60) 
 
 
 
  
Figure 1. Kaplan-Meier curves for the entire time span. The percentage of patients without 
an AE by months of Follow up 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Median time-to-shock by different parameters. The median time-to-shock for the 
overall group was 24.4±2.8 months. The figure displays the comparison of the median time-
to-shock by different patient characteristics: gender, ethnicity, symptoms, ECG type, family 
history of SCD, mutation, EPS results and ICD indication. (see text for elaboration).  
 
 
 
Figure 3. Predictors of ≤ than 5 years to shock (OR) Univariate logistic regression for 
factors favoring ≤ than 5 years to shock delivery.  
 
Figure 4. TScore - The Time-to-Shock Score (TScore). Panel A: This risk score sums the 
following risk factors found to have significance for an earlier AE after a prophylactic ICD 
implantation: One point is given for either prior syncope or the presence of a spontaneous 
type 1 Brugada-ECG. Panel B: A gender augmented score, using both the above risk factors 
and 2 points for female gender. P-value for trend between the score and the probability 
<0.001 for both scores. 
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ABSTRACT 
Aims. 
Data on predictors of time-to-first appropriate ICD therapy in patients with Brugada 
syndrome (BrS) and prophylactically implanted ICD’s are scarce.  
Methods. 
SABRUS is an international survey on 678 BrS-patients who experienced arrhythmic 
event (AE) including 252 patients in whom AE occurred after prophylactic ICD 
implantation. Analysis was performed on time-to-first appropriate ICD discharge 
regarding patients’ characteristics. Multivariate logistic regression models were 
utilized to identify which parameters predicted time to arrhythmia ≤ 5 years.  
Results. 
The median time-to-first appropriate ICD therapy was 24.8±2.8 months. A shorter 
time was observed in patients from Asian ethnicity (p<0.05), those with syncope 
(p=0.001) and those with class IIa indication for ICD (p=0.001). A longer time was 
associated with a positive family history of sudden cardiac death (p<0.05). 
Multivariate Cox regression revealed shorter time-to-ICD therapy in patients with 
syncope (OR 1.65, P=0.001). In 193 patients (76.6%), therapy was delivered during 
the first 5 years. Factors associated with this time were syncope (OR 0.36, p=0.001), 
spontaneous type 1 Brugada ECG (OR 0.5, p<0.05) and class IIa indication (OR 0.38, 
p<0.01) as opposed to class IIb (OR 2.41, p<0.01). A near-significant trend for female 
gender was also noted (OR 0.13, p=0.052). Two score models for prediction of <5 
years to shock were built. 
Conclusions.  
First appropriate therapy in BrS-patients with prophylactic ICD’s occurred during the 
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first 5 years in 76.6% of patients. Syncope and spontaneous type 1 Brugada-ECG 
correlated with a shorter time to ICD therapy. 
 
Key Words: Brugada Syndrome, ICD, appropriate therapy, arrhythmic event 
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Condensed abstract. 
SABRUS collected 252 patients in whom AE occurred after prophylactic ICD 
implantation. First appropriate ICD therapy occurred during first 5 years in 76.6% of 
patients. Syncope and spontaneous type 1 Brugada-ECG (comprising class IIa 
indication for prophylactic ICD implantation) correlated with shorter time to ICD 
therapy. 
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'What's New?'  
1. In patients with BrS who had an appropriate shock from a prophylactically 
implanted ICD, the great majority (76.6%) received this shock during the first 
5 years after ICD implantation.  
2. Clinical parameters predicting a shorter time to appropriate shock were 
syncope and a spontaneous type 1 ECG. A near-significant trend for female 
gender was also noted. 
3. Two score models were built using these parameters to predict the time to 
first AE and will need to be validated in future studies.  
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INTRODUCTION 
Brugada syndrome (Brs) is a well-recognized cause of sudden cardiac death (SCD) 
particularly in apparently healthy middle-aged males(1). The cause of death is a 
ventricular tachyarrhythmia usually occurring without precipitating warning signs(2) .  
Most clinical research on this potentially lethal arrhythmic disease has mainly 
focused on risk stratification to identify patients at risk who will benefit from an 
implanted cardioverter-defibrillator (ICD), the most advocated option to prevent 
SCD.  
Present indications for prophylactic ICD implantation in patients with BrS-ECG 
include(3): 1) Spontaneous type 1 Brugada-ECG pattern and a history of syncope 
(class IIa indication); 2) Spontaneous or drug-induced type 1 Brugada-ECG with 
induction of ventricular fibrillation during programmed ventricular stimulation with 2 
or 3 extrastimuli (class IIb indication). When a patient is identified as complying with 
these guideline recommendations(3), the most appropriate timing of the 
implantation is unknown with a double-edged sword decision for implant:  too early 
might expose the patient to possible complications whereas too late might have a 
detrimental outcome.  
SABRUS is a multicenter international survey that collected data on a large cohort 
(n= 678) of BrS-patients who experienced AE including 252 patients in whom the AE 
occurred after a prophylactic ICD implantation. 
The present study sought to gain insight into the factors that affect the time-to-first 
appropriate ICD therapy in all the 252 BrS patients who received a prophylactic ICD.  
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METHODS   
Study group. As mentioned in previous papers(1, 2), the SABRUS cohort population 
comprised a total of 678 BrS-patients with AE who were recruited from 23 centers 
from both 10 Western countries (426 patients; 62.8%) and 4 Asian countries (252 
patients; 37.2%).  In 426 patients (group A), the AE was documented during aborted 
CA while in 252 patients (group B) the AE was documented from an ICD implanted 
prophylactically following conventional class IIa or IIb indications(3) (75% of patients) 
or non-class IIa or IIb indications (25% of patients)(2). 
Group B patients comprised the study group of the present study.  
The study was approved by the Research Ethics Boards of all participating 
institutions. 
DATA ACQUISITION. 
Anonymous patient information was collected using a predefined questionnaire 
regarding the following: 1) gender; 2) patient age at time of ICD implantation; 3) 
date of ICD implantation; 4) date at which the first AE occurred after ICD 
implantation; 4) ethnicity (Caucasian, Asian, other or unknown); 5) proband status; 
6) family history of SCD;  7) prior history of syncope ; 8) presence of spontaneous or 
drug-induced Brugada-ECG type 1; 7) inducibility of sustained ventricular fibrillation 
(VF) at EP study (EPS) and 9) results of genetic testing for the presence of SNC5A 
mutation. 
DEFINITIONS. 
Arrhythmic events: AE was defined as any sustained ventricular tachyarrhythmia 
triggering appropriate ICD shock therapy. 
STATISTICAL ANALYSIS.   
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Estimation of median time to AE for ordinal variables was done using Kaplan-Meier 
curves; significance of the difference between two curves was calculated using the 
log-rank test. Multivariate time to AE analysis and analysis of continuous parameters 
was done using Cox regression models. Calculation of each parameter effect on 
probability of time to AE being >5 years was done using binary logistic regression 
models. To prevent detection bias due to patients with longer follow up having a 
longer time to AE, we added the year of ICD implantation in all of the multivariate 
analyses to cancel out this effect. Out of the multivariate logistic regression model 
we built prediction scores using the relative odd ratios as a guide to each parameter 
score. The trend between the scores and the above probability was assessed using 
Mantel-Haenszel test of trend and the highest-ranking scores were selected. Time to 
AE is shown as Median ± SE. P-values were considered significant when P<0.05, all 
calculations were done using SPSS v.24 from IBM, Armonk, Virginia.                    
RESULTS 
Study group.  The study group comprised 252 patients aged 1.1-77.5 (mean 46.1 ± 
13.3) years at time of AE, most being males (n= 229, 91%) and Caucasians (n= 160, 
63.5 %) (Supplemental Table 1).  A positive family history of SCD and a prior history 
of syncope were present in 29% and 63% of patients, respectively. A spontaneous 
type 1 Brugada-ECG was observed in 69% of patients. Most of the patients (79%) 
underwent an EPS during which VF was inducible in 72% of them. Genetic testing 
was performed in 67% of patients and revealed an SCN5A mutation in 36% of them. 
The age at time of ICD implantation ranged from 1-73.2 years (mean 43.4±13.1). 
Time-to-shock. The time-to-shock ranged from 0 to 168.4 months (median 24.4±2.8 
months), Figure 1 shows the Kaplan Meier curves for the entire time span. Table 1 
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elaborates the comparison of the median time-to-shock according to different 
patient characteristics and Figure 2 displays the results. The following two factors 
were found to be associated with a significantly shorter time-to-shock: Asian vs. 
Caucasian ethnicity (16.5±4.8 vs. 30.9±16.5 months respectively, P<0.05) and a prior 
history of syncope vs. being asymptomatic (19.5±2.5 vs. 36.5±4.9 months 
respectively, P=0.001). In contrast a positive family history of SCD resulted in a 
longer time-to-shock (33.5±4.8 vs. 21.2±3.1 months in patients without such a 
history, P<0.05). 
In respect to the conventional indications of prophylactic ICD implantation (3), the 
shortest median time-to-shock was observed in the class IIa subgroup (17.8±3.5 
months) as compared to class IIb subgroup (37.2±4.2 months, P=0.001) or to non 
IIa/IIb indications (29.6±2.8 months, P=0.058)  
Univariate Cox regression for continuous variables did not find a significant relation 
between a shorter time-to-shock and patient age at time of ICD implantation 
[P=0.285; odds ratio [OR]. 1.06; 95% confidence interval (CI). 0.96-1.17]. Multivariate 
Cox regression was significant for a history of syncope [P=0.001; OR 1.65; 95% CI 
1.21-2.25] and for year of ICD implantation [P<0.001; OR 1.12; 95% CI 1.07-1.16] but 
not for ethnicity or family history of SCD.  
Less than 5 years-to-shock time. Table 2 shows patients characteristics in respect to 
a 5 years-to-shock time. In 193 (76.6%) patients appropriate ICD shock therapy was 
delivered during the first 5 years.  Univariate logistic regression (Figure 3) analyses 
showed that factors favoring this time lag were a prior history of syncope (P=0.001, 
OR. 0.36; 95% CI 0.2-0.65), the presence of a spontaneous type 1 Brugada-ECG 
(P<0.05, OR. 0.5; 95% CI 0.27-0.92) and the year of ICD implantation (P<0.001; OR. 
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0.87; 95% CI 0.82-0.94). Female gender showed a trend towards shock time less than 
5 years (P=0.052, OR. 0.13; 95% CI 0.02-1.02), Multivariate Cox regression analysis 
was significant for all the aforementioned parameters (Supplemental Table 3).  
Opposite results were found between the class IIa and IIb indications for 
prophylactic ICD implantation: a class IIa indication was a significant predictor for < 5 
years-to-appropriate shock (P<0.01; OR. 0.38; 95% CI 0.2-0.71) whereas a class IIb 
indication was a significant predictor for > 5 years-to-appropriate shock (P<0.01; OR. 
2.41; 95% CI 1.32-4.22) (Figure 3). 
 Time-to-Shock Score. Taking into consideration the aforementioned patients’ 
characteristics predicting a time-to-shock < 5 years, their relative odds ratio, and 
parameter significance, two risks scores were built.  One with a history of syncope 
and spontaneous type 1 Brugada ECG (minimal score) and the second with female 
gender added, as it had a borderline significance, yet we postulated it could add 
power to the score (gender augmented score).   
These Scores sum the risk factors found to have significance for an earlier AE after a 
prophylactic ICD implantation. Each risk factor received a score between 1 and 2 and 
the sum gives the percentage of patients who received an appropriate therapy 
during the first 5 years from the implant (Figure 4). One point is given for either prior 
syncope or the presence of a spontaneous type 1 Brugada-ECG, and for the gender 
augmented score - 2 points were added for female gender. The scores range 
between 0 and 2 for the minimal score and 0 and 4 for the gender augmented score. 
A score of 0 was found in 50.0% of patients using the minimal score and in 46.4% of 
patients using the gender augmented score. A maximal score (2 in the minimal score 
system and 4 in the gender augmented system) was observed in 85% and 100% of 
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patients, respectively. The trend between the score and the percentage of patients 
with time to shock less than 5 years was highly significant for both scores (p<0.001 
for both) but reached a higher level for the gender augmented score (Mantel-
Haenszel statistics of 16 and 20.1 for the minimal and the gender augmented scores, 
accordingly).  
DISCUSSION 
Our study showed that the median time-to-first appropriate ICD therapy in the 252 
BrS patients who received a prophylactic ICD was 24.8±2.8 months. The shortest 
times were observed in patients of Asian ethnicity, in those with prior syncope and in 
those who had a class IIa indication for ICD implantation. The longest time was 
associated with a positive family history of SCD. In > 3 quarters of the study patients, 
appropriate ICD therapy was delivered during the first 5 years after implantation, 
especially in patients with a female gender, those with a prior syncope and those 
with a spontaneous type 1 Brugada-ECG. Two score models for predicting a time-to-
shock ≤5 years were built according to the significance of the parameters; one 
included syncope and a type 1 Brugada ECG and the second included female gender 
which had a borderline significance and resulted in a 100% accuracy when patients 
exhibited all these characteristics. 
Time-to-shock. 
The literature regarding the time-to-first appropriate shock therapy in BrS patients 
implanted prophylactically with an ICD is scarce. Only 3 studies report their results 
on small patient cohorts (ranging from 7 to 34 patients)(4-6). Sarkozy et al.(5) found 
a mean time-to-first appropriate therapy of 13 months (3 days to 4 years) in 7 male 
patients including 3 with a history of syncope. They did not find a significant 
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predictor of appropriate shock-free survival(5). In an earlier study, Sacher et al.(4) 
demonstrated that the asymptomatic group (n=5) had a shorter median time-to-
shock (16 months) than the syncope group (n=9) (24 months)(4). However, in a latter 
larger study by the same group with prolonged follow-up duration, time-to-shock 
lengthened with no difference found between the symptomatic (47 months, n=22) 
and asymptomatic (45 months, n=12) groups(6). 
 In the present study which involved the largest cohort population with AEs 
documented after prophylactic ICD implantation (n=252), the median time-to-shock 
was 24.8 months.  Asian ethnicity and a history of syncope were predictors of a 
shorter time-to-shock, suggesting these factors should be taken into consideration 
when contemplating ICD implantation. This is consistent with the fact that group IIa 
patients had the shortest time-to-shock.  
By multivariate logistic regression the presence of syncope was found to correlate 
with a shorter time-to-shock (19.5±2.5 months vs. 36.5±4.9 months in asymptomatic 
patients, P<0.001). It is noteworthy that these results are in agreement with those of 
the FINGER study(7) where time-to-first event was reported to be significantly 
shorter in the syncope group patients than in the asymptomatic group.  
In the present study, a positive family history of SCD correlated with a longer time-
to-shock, however these findings should be considered with caution since they were 
seen only in the univariate analysis and not in the multivariate one. One possible 
explanation could be a biased decision taken by the referring patient’s physician who 
considered a family history of SCD as a major risk factor. On the other hand, we 
already stressed elsewhere the problematic definition of family history of SCD in our 
study(2).  ICD implant year was a predictor of early AE, mostly due to longer follow-
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up in patients that had an ICD implanted in the past, although this finding might also 
represent different trends in ICD implant indications, and changes in ICD arrhythmia 
detection algorithms.   
Time-to-shock within 5 years. 
Considering the lifesaving properties of ICD in comparison to its non-negligible 
complication rate together with the low incidence of AE requiring ICD intervention in 
BrS patients implanted prophylactically, up to a 5-year time-to-shock was chosen as 
accounting for a well-timed implant. Our study found that syncope and a 
spontaneous type 1 Brs-ECG were significantly associated with time-to-shock of ≤5 
years. Therefore, it is not surprising that group IIa patients which included those with 
syncope and a spontaneous type 1 BrS-ECG belonged to this 5 years’ time-to-shock 
period. Moreover, the fact that in contrast group IIb patients exhibited their AE more 
than 5 years after implantation is in congruence with the lower risk of AE found in 
group IIb as compared to group IIa patients(8).  
Our study showed that 96% of female patients vs. 75% of males had their AE’s ≤ 5 
years after ICD implant. In our recent paper(9) we discussed several factors 
suggesting a more aggressive course of the disease in females. This should support 
an early implantation of ICD in females found to be at high risk. 
Time-to-shock Score  
The time-to-shock score (TScore) was created to help the identification of patients 
who will need an ICD implant with the shortest delays. The significant risk factors 
found in our study to be associated with a time-to-shock ≤ 5 years were attributed a 
score according to their statistical significance. Because female gender had a 
borderline significance (p=0.052), which could be a result of the low number of 
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females included in the study, we created two scores one including gender and one 
excluding it.  Both scores showed high prediction rates for AE ≤ 5 years after ICD 
implant, yet the gender augmented score showed a more significant trend with a 
higher predictive value for the maximal score (85% for the maximal score in the 
minimal scoring system vs. 100% for the gender augmented system). As indicated in 
Figure 3, the absence of any of these risk factors, results in a risk of ~50% chance of 
exhibiting an AE ≤ 5 years after ICD implant. Thus, patients with a score of 0 could be 
implanted less urgently. On the other hand, a maximal score of 4 (i.e. a female with 
syncope and a spontaneous type 1 BrS-ECG) in the gender augmented system should 
lead to ICD implant with the shortest delays. The value of this TScore should be 
further validated and assessed prospectively in future studies, where the question of 
the influence of gender could also be assessed more accurately. 
Limitations  
The present study by nature is a retrospective cumulative analysis of results from the 
largest EP-centers with experience with BrS. The decision to implant a prophylactic 
ICD in those patients who did not fulfill class II indications was left to the discretion 
of the treating physician. We acknowledge that defining risk factors without a 
comparative group of asymptomatic patients is problematic and that the results 
should be prospectively tested in future studies. Also, our cohort was probably not 
powered enough to assess the influence of female gender as resulted in a borderline 
significance for a time to shock of less than 5 years.   
Conclusion 
The present study describes for the first time, in a large cohort of BrS patients with 
AE’s documented after prophylactic ICD implantation, the characteristics of those 
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who exhibited their AE within 5 years.  Two factors (syncope and spontaneous type 1 
BrS-ECG) were found to be associated with this time-to-shock delay.  A score based 
on these factors is proposed and should be assessed prospectively.  
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Table 1. Comparison of the median time-to-shock by different patient 
characteristics. 
 
 
    
Time-to-shock  
p-
value months 
(Median±SE) 
Overall   24.4±2.8   
Gender 
Male 25.3±3.2 
0.458 
Female 21.5±3.5 
Ethnicity 
Caucasian 30.9±16.5 
0.036 
Asian 16.5±4.8 
Family history of SCD 
Yes 33.5±4.8 
0.019 
No 21.2±3.1 
Prior history of syncope 
Yes 19.5±2.5 
0.001 
No 36.5±4.9 
Spontaneous type 1 ECG 
Yes 23.5±2 
0.258 
No  36.1±7.7 
VF inducibility during EPS 
Positive EPS 25.5±4.8 
0.426 
Negative EPS 24.2±6.9 
EPS not 
performed 
21.2±4.6 
Presence of SCN5A 
mutation 
SCN5A positive 22.6±5.2 
0.799 
SCN5A negative 24.4±4.2 
Class of indication for ICD 
IIa 17.8±3.5 
0.003*,# IIb 37.2±4.2 
No IIa or IIb 29.6±2.8 
 
 
 IIa vs. IIb, P=0.001; # IIa vs. No, P=0.058 
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Table 2. Characteristics of patients in respect to the appropriate time-to-shock 
(less or more than 5 years) delivery.   
 
  
Time to AE 
p-value ≤5 years  >5 years 
193(76.6) 59(23.4) 
Gender 
Male 171(88.6) 58(98.3) 
0.045 
Female 22(11.4) 1(1.7) 
Ethnicity 
Caucasian 119(61.7) 41(69.5) 
0.48 
Asian 62(32.1) 16(27.1) 
Other 4(2.1) 0(0) 
0.613 
Unknown 8(4.1) 2(3.4) 
Family history of SCD 
Yes 52(26.9) 20(33.9) 
0.278 
No 122(63.2) 31(52.5) 
Unknown 19(9.8) 8(13.6) 0.571 
Prior history of syncope 
Yes 133(68.9) 26(44.1) 
0.001 
No 60(31.1) 33(55.9) 
Spontaneous type 1 ECG 
Yes 141(73.1) 34(57.6) 
0.037 
No  52(26.9) 25(42.4) 
VF inducibility during EPS 
Not performed  42(21.8) 10(16.9) 0.538 
Positive EPS 107(70.9) 37(75.5) 
0.529 
Negative EPS 44(29.1) 12(24.5) 
Presence of SCN5A mutation 
Not performed 60(31.1) 24(40.7) 0.226 
SCN5A positive 47(35.3) 14(40) 
0.609 
SCN5A negative 86(64.7) 21(60) 
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Figure 1. Kaplan-Meier curves for the entire time span. The percentage of patients 
without an AE by months of Follow up 
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Figure 2. Median time-to-shock by different parameters. The median time-to-shock 
for the overall group was 24.4±2.8 months. The figure displays the comparison of the 
median time-to-shock by different patient characteristics: gender, ethnicity, 
symptoms, ECG type, family history of SCD, mutation, EPS results and ICD indication. 
(see text for elaboration).  
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Figure 3. Predictors of ≤ than 5 years to shock (OR) Univariate logistic regression 
for factors favoring ≤ than 5 years to shock delivery.  
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Figure 4. TScore - The Time-to-Shock Score (TScore). Panel A: This risk score sums 
the following risk factors found to have significance for an earlier AE after a 
prophylactic ICD implantation: One point is given for either prior syncope or the 
presence of a spontaneous type 1 Brugada-ECG. Panel B: A gender augmented score, 
using both the above risk factors and 2 points for female gender. P-value for trend 
between the score and the probability <0.001 for both scores. 
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